

# Robert F Cornell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3358583/publications.pdf>

Version: 2024-02-01

66  
papers

2,879  
citations

331538

21  
h-index

175177

52  
g-index

72  
all docs

72  
docs citations

72  
times ranked

3513  
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 2022, 97, .	2.0	11
2	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 2901-2912.	0.8	124
3	Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. Cancer Medicine, 2022, 11, 358-370.	1.3	6
4	Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. American Journal of Hematology, 2022, 97, 1170-1177.	2.0	3
5	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	3.3	69
6	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <sc>MAMMOTH</sc>. American Journal of Hematology, 2021, 96, E5-E8.	2.0	20
7	Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 645122.	1.1	9
8	KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 526-535.	0.2	10
9	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer, 2021, 21, 993.	1.1	8
10	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial. Blood, 2021, 138, 481-481.	0.6	5
11	Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy. Blood, 2021, 138, 483-483.	0.6	2
12	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <sc>C</sc>ardio&lt;sc>O</sc>ncology <sc>S</sc>tudy <sc>G</sc>roup of the <sc>H</sc>eart <sc>F</sc>ailure <sc>A</sc>ssociation of the <sc>E</sc>uropean <sc>S</sc>ociety of <sc>C</sc>ardiology in collaboration with the <sc>I</sc>nternational <sc>C</sc>ardio&lt;sc>O</sc>ncology <sc>S</sc>ociety. European Journal of Heart Failure, 2020, 22, 1137-1146.	2.9	364
13	Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. Frontiers in Oncology, 2020, 10, 815.	1.3	19
14	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440.	3.3	54
15	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological Oncology, 2020, 38, 353-362.	0.8	14
16	Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1137-1146.	1.3	7
17	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	3.3	27
18	Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. British Journal of Haematology, 2020, 190, 555-561.	1.2	36

#	ARTICLE	IF	CITATIONS
19	Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients.. Journal of Clinical Oncology, 2020, 38, 8515-8515.	0.8	1
20	Mortality of multiple myeloma diagnosed peri-hospitalization.. Journal of Clinical Oncology, 2020, 38, e20553-e20553.	0.8	0
21	Association of elevated red cell distribution width and overall survival in multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8534-8534.	0.8	0
22	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	13.9	460
23	Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. British Journal of Haematology, 2019, 186, 807-819.	1.2	14
24	Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2019, 37, 1946-1955.	0.8	128
25	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. American Journal of Hematology, 2019, 94, 794-802.	2.0	10
26	Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management. Current Oncology Reports, 2019, 21, 29.	1.8	19
27	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia, 2019, 33, 2266-2275.	3.3	385
28	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. Frontiers in Oncology, 2019, 9, 45.	1.3	22
29	Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cells. BMJ Case Reports, 2019, 12, e231314.	0.2	0
30	Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2019, 134, 1869-1869.	0.6	36
31	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2019, 134, 860-860.	0.6	80
32	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. Blood, 2019, 134, 3125-3125.	0.6	10
33	A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or NaÃ“ve to Daratumumab (dara). Blood, 2019, 134, 1867-1867.	0.6	5
34	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1154-1165.	2.3	113
35	Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 335-345.	0.2	88
36	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2018, 59, 2588-2594.	0.6	22

#	ARTICLE	IF	CITATIONS
37	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 180, 271-275.	1.2	24
38	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	0.8	140
39	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.4	47
40	Second primary malignancy after multiple myeloma—population trends and cause-specific mortality. <i>British Journal of Haematology</i> , 2018, 182, 513-520.	1.2	25
41	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
42	Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy. <i>Blood</i> , 2018, 132, 1233-1233.	0.6	2
43	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. <i>Blood</i> , 2018, 132, 2015-2015.	0.6	10
44	Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8022-8022.	0.8	2
45	A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3103-TPS3103.	0.8	7
46	Current Concepts of Cardiac Amyloidosis. <i>Heart Failure Clinics</i> , 2017, 13, 409-416.	1.0	28
47	Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1473-1477.	2.0	5
48	The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis. <i>British Journal of Haematology</i> , 2017, 177, 481-483.	1.2	11
49	Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 529-532.	2.0	16
50	Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 205-211.	1.4	14
51	Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma. <i>Cardio-Oncology</i> , 2017, 3, 4.	0.8	13
52	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
53	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
54	Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, e204-e208.	1.7	1

#	ARTICLE	IF	CITATIONS
55	Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making. American Journal of Hematology, 2016, 91, 1044-1051.	2.0	8
56	Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. Biology of Blood and Marrow Transplantation, 2015, 21, 2061-2068.	2.0	87
57	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology, 2015, 33, 3741-3749.	0.8	163
58	Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis. Blood, 2015, 126, 1841-1841.	0.6	1
59	Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM). Blood, 2015, 126, 396-396.	0.6	2
60	Functional improvement measured by the six-minute walk test after chemotherapy in cardiac AL amyloidosis.. Journal of Clinical Oncology, 2015, 33, e19539-e19539.	0.8	0
61	In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant. Blood, 2015, 126, 5493-5493.	0.6	0
62	Why Waldenström macroglobulinemia is not just another indolent lymphoma. International Journal of Hematologic Oncology, 2014, 3, 95-98.	0.7	2
63	Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1368-1373.	2.0	29
64	Chemotherapy-Induced Regression of an Adrenocorticotropin-Secreting Pituitary Carcinoma Accompanied by Secondary Adrenal Insufficiency. Case Reports in Endocrinology, 2013, 2013, 1-10.	0.2	13
65	Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL). Blood, 2011, 118, 1880-1880.	0.6	0
66	Patterns of Myeloma (MM) Progression After Autologous Transplant (AHCT) - Biochemical Progression Vs. Clinical Relapse. Blood, 2011, 118, 5097-5097.	0.6	0